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Abstract
Aims/hypothesis Type 2 diabetes is a progressive disease that
increases morbidity and the risk of premature death. Glucose
dysregulation, such as elevated fasting blood glucose, is
observed prior to diabetes onset. A decline in beta cell insulin
secretion contributes to the later stages of diabetes, but it is not
known what, if any, functional beta cell changes occur in
prediabetes and early disease.
Methods The Leprdbmouse (age 13–18 weeks) was used as a
model of type 2 diabetes and a two-photon granule fusion
assay was used to characterise the secretory response of
pancreatic beta cells.
Results We identified a prediabetic state in db/db mice where
the animals responded normally to a glucose challenge but
have elevated fasting blood glucose. Isolated islets from
prediabetic animals secreted more and were bigger. Insulin
secretion, normalised to insulin content, was similar to wild
type but basal insulin secretion was elevated. There was
increased glucose-induced granule fusion with a high
prevalence of granule–granule fusion. The glucose-induced
calcium response was not changed but there was altered
expression of the exocytic machinery. db/db animals at the
next stage of disease had overt glucose intolerance. Isolated
islets from these animals had reduced insulin secretion,
reduced glucose-induced granule fusion events and decreased
calcium responses to glucose.
Conclusions/interpretation Beta cell function is altered in
prediabetes and there are further changes in the progression
to early disease.
Keywords Beta cell . Compound exocytosis . Exocytosis .
Insulin granules . Islets . Prediabetes . Progression
Abbreviations
FBG Fasting blood glucose
GTT Glucose tolerance test
IFG Impaired fasting glucose
IGT Impaired glucose tolerance
qPCR Quantitative real-time PCR





Type 2 diabetes is a chronic, progressive disease characterised
by loss of glucose homeostasis and leading to morbidity and
premature mortality [1–4]. A key feature of the later disease
stages is the failure of insulin secretion from beta cells to meet
the demand of increased peripheral insulin resistance [1, 5].
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However, in early disease there can be an increase in insulin
secretion that might be explained by an increase in beta cell
mass; nevertheless, it is unknown whether beta cell function
also changes. Here, we have used the Leprdb mouse model of
diabetes to investigate beta cell function in early disease.
Prior to overt type 2 diabetes, a prediabetic state can be
identified by impaired fasting glucose (IFG) or impaired
glucose tolerance (IGT) after a glucose tolerance test
(GTT). A study of prediabetic individuals (identified by
IFG) showed increased insulin secretion in response to an
OGTT [6]. Some studies have also shown that individuals
with IGT have enhanced insulin secretion [6, 7], but it is
not known whether this is due to upregulation of beta cell
secretion or an increased number of beta cells [3].
There is indirect evidence that compensatory increases in
beta cell number can occur in obese humans [8, 9] and in
animal models such as prediabetic Zucker diabetic fatty rats
[10], TALLYHO diabetic mice [11], ob/ob mice [12] and
animals fed a high-fat diet [13–15].
There is no direct evidence that beta cell function changes
in prediabetes or early disease. However, it is known to occur
in other contexts. For example beta cell secretory function is
enhanced in pregnancy to cope with the increased demand
from the developing fetus [16]. Moreover, in the ob/obmodel
of obesity, in addition to increased numbers of beta cells, there
is increased secretion per cell [12].
In this paper, we describe experiments using the Leprdb
mouse model of type 2 diabetes [17] aimed at understanding
beta cell function during prediabetes and early disease. Our
results show beta cells do undergo functional changes during
prediabetes and their exocytic capacity is upregulated in
response to glucose. We conclude that pathological changes
are already occurring in beta cells during prediabetes.
Methods
Glucose tolerance test We performed i.p. glucose tolerance
tests (1 g/kg body weight) for wild-type (WT, +/+) and all
db/db mice (see electronic supplementary material [ESM]
Methods for details).
Cell preparation Mice of both sexes and aged 13–18 weeks
were used, except where otherwise stated (BKS.Cg-
Dock7m+/+Leprdb/J, The Jackson Laboratory, Bar Harbor,
ME, USA) were humanely killed according to local animal
ethics procedures (approved by the University of Queensland
Anatomical Biosciences Ethics Committee). Islets were pre-
pared by enzymatic digestion of the pancreas from WT, stage
1 and stage 2 db/db mice for experiments (except the insulin
assay, which was performed in WT and db/db mice of all
stages; see ESM Methods for details).
Experimental solution Two-photon imaging, insulin assays
and calcium measurements were performed in a sodium-rich
extracellular solution (see ESM Methods for details).
Two-photon imaging Isolated islets were first cultured for
2–3 days and then prior to imaging were bathed in an extra-
cellular solution containing 3 mmol/l glucose for 30 min
(37°C, 95%/5% air/CO2). Islets were then transferred to an
extracellular solution containing 15 mmol/l glucose and
0.8 mmol/l sulforhodamine B (SRB). Two-photon imaging
was performed at 34°C, with exocytic events recorded as entry
of the SRB extracellular dye (excitation 950 nm, detection
550–650 nm) into each fused granule (see ESM Methods for
details).
Insulin assay Homogeneous time resolved fluorescence with
the HTRF Insulin Kit (no. 62INSPEB, Cisbio Bioassays,
Brisbane, QLD, Australia) was used to measure islet insulin
secretion (see ESM Methods for details).
Calcium measurement For intracellular calcium measure-
ment, we used the ratiometric calcium indicator Fura2-AM
(see ESM Methods for details).
Immunofluorescence Freshly isolated islets were fixed in 4%
paraformaldehyde, permeabilised with Triton X-100 and
blocked with donkey serum containing BSA for 1 h prior to
incubation with primary antibodies (see ESM Methods for
details).
Quantitative real-time PCR Total RNA was isolated from
islets using RNeasy plus Micro kit (Qiagen). cDNA was
synthesised from 100 ng total RNA using the SuperScript
III reverse transcriptase (Invitrogen, Mt Waverley, VIC,
Australia; see ESM Methods for details).
Serial block-face scanning electron microscopy Islets
cultured for 2 days were stimulated with 15 mmol/l glucose
for 7 min and then fixed with 2.5% glutaraldehyde and
processing for imaging (see ESM Methods for details).
Statistical analyses All numerical data are presented as the
mean ± SEM. Statistical analysis was performed using
Microsoft Excel 2010 (Microsoft Corporation, Redmond,
WA, USA) and GraphPad Prism version 6 (La Jolla, CA,
USA). Datasets containing just two groups were subjected to
a two-tailed, unpaired Student’s t test with statistical signifi-
cance identified at p<0.05. Islets from at least three animals
were used in each experiment. Statistical significance is
indicated in the figures as *p < 0.05, **p < 0.01, and
***p< 0.001.
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Results
The Leprdb spontaneousmutant (BKS.Cg-Dock7m+/+Leprdb/J)
is a recognised mouse model for type 2 diabetes [17]. The
db/db animals gained weight and developed disease, as
assessed in 13–18-week-old animals using GTTs (Fig. 1a;
seven WT, four db/+, 105 db/db mice). As in human disease
[18], there is great variability in phenotype among individual
animals. In db/db animals, the AUC (derived from the
GTTs) ranged from normal to a fivefold increase (Fig. 1b).
We categorised the AUC into four stages of severity, stage 1
(compensation) to stage 4 (severe disease), analogous to
those of human disease [3]. Performing GTTs before each
animal was sacrificed thus enabled us to classify the severity
of their disease.
We next tested islet function to determine whether insulin
secretion changed according to the stage of disease severity.
Isolated islets were stimulated for 20 min with 3 or 15 mmol/l
glucose. At stage 1, db/db islets showed a significant increase
in insulin secretion at both 3 and 15 mmol/l glucose compared
with WT (Fig. 1c; 24 WT and 25 db/db mice). At stage 2,
insulin secretion decreased to levels resembling those of
WT islets; at stage 3, there was a further decrease in insulin
secretion; and at stage 4, insulin secretion was significantly
lower than in WT islets (Fig. 1c).
We used this classification to subdivide the animals’
phenotype. At stage 1, db/db animals were heavier than WT
(Fig. 1d), with no significant difference in the GTT (Fig. 1e)
and a small, but significant, increase in fasting blood glucose
(FBG) (Fig. 1f). By stage 2, the bodyweight, GTTand FBG of
db/db animals all differed significantly from those of WT
animals and were indicative of frank diabetes (Fig. 1d–f).
These changes approximate to the progression of human
type 2 diabetes.
Islet size and insulin content increase in prediabetes The
basis of increased insulin secretion during the prediabetic
phase could be an increase in islet size. Consistent with this,
islets isolated from WT, stage 1, and stage 2 db/db animals
showed an increase in islet size (Fig. 2a–d) and insulin content
(Fig. 2e). The islet composition also changed: there was a
decreased relative percentage of alpha cells (Fig. 2g). When
normalised to the islet content, the increase in basal secretion
persisted but the increase in glucose-induced secretion
(Fig. 1c) was no longer apparent (Fig. 2f). We therefore
expected to see little change in secretory output per cell.
Insulin secretion during stage 1 shows upregulation of the
exocytic capacity To study secretory function within individ-
ual beta cells in intact islets, we used a two-photon, granule
fusion assay that we previously used to characterise the fusion
of individual insulin granules from beta cells within intact
islets [19]. When recording from the islet core, where most
cells are beta cells (see Fig. 2g), this method detects the fusion
of granules that are the same size as insulin granules,
colocalise with insulin and, in terms of fusion numbers, fully
account for insulin secretion from the islets [19].
Islets were stimulated with 15 mmol/l glucose for 20 min.
As each granule fuses with the cell membrane, extracellular
dye enters the granule, thus enabling the precise spatial and
temporal localisation of the fusion event (Fig. 3a). Compared
withWT islets, there are more granule fusion events in stage 1
islets, demonstrating that functional changes are occurring in
beta cells. At stage 2, there are fewer granule–granule fusion
events compared with WT. This was expected because these
animals have overt diabetes, and has been previously reported
by us [20].
The increased exocytic response at stage 1 reflects both an
apparent increase in the numbers of cells responding to
glucose and an increase in the number of fusing granules
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Fig. 1 Classification of db/db animals into separate stages of disease. (a)
The overall mean GTT was significantly impaired in db/db (triangles)
compared with WT (+/+; circles) and +/− mice (squares). (b) db/dbmice
(black bars) are classified into four stages based on the AUC for the GTT:
stage 1, <1,600 mmol/l ×min; stage 2, 1,600–2,200 mmol/l ×min; stage
3, 2,200–2,800 mmol/l ×min; stage 4, >2,800 mmol/l ×min. White bars,
WT. (c) Glucose-induced islet insulin secretion is increased at stage 1 and
reduced for the later stages of disease. (d) Stage 1 animals are significant-
ly heavier thanWT (+/+) animals. (e) GTT is comparable in stage 1 db/db
(dotted line) and WT (+/+) islets (solid line) but significantly increases in
stage 2 db/db islets (dashed line). (f) Stage 1 db/dbmice have a small but
significant increase in FBG. *p< 0.05, **p< 0.01, ***p< 0.001 vs WT
1224 Diabetologia (2016) 59:1222–1230
that individual beta cells have become more responsive to a
glucose stimulus.
These data were all obtained from 13- to 18-week-old
animals. To test whether the db/db animals were born with the
increased insulin granule exocytosis seen at stage 1 or
progressed to this point, we studied 6-week-old db/db animals
classified as stage 1 by their GTT responses. These animals
had not yet developed abnormal FBG; in addition, their islet
diameter, insulin content and insulin secretion were indistin-
guishable from those of WT animals (Table 1). After glucose
stimulation, the number of exocytic events in 6-week-old
db/db animals was not different from that of age-matchedWT
animals (Fig. 3b). These data indicate that the enhanced
granule–granule fusion seen in stage 1 animals aged
13–18 weeks is an adaptive response to disease progression.
These changes in insulin granule fusion could be due to
changes in the exocytic machinery or to upstream changes,
such as altered calcium responses that are triggered by glu-
cose. Using Fura-2 loading, we showed higher resting calcium
levels in stage 1 db/db than in WT islets (64±6.8 nmol/l in




























































































Fig. 3 Glucose-induced insulin granule fusion is substantially altered in
db/db islets. (a) A two-photon granule fusion assay identified the sites of
granule fusion events (yellow circles) over a 20 min period in response to
15 mmol/l glucose. Compared with WT (+/+), many more fusion events
are seen in stage 1 db/db islets, with greater spatial clustering of fusion
events. In contrast, stage 2 db/db islets show a dramatic decrease in fusion
events. Histograms show changes in granule exocytosis in terms of the
numbers of responding cells and responses per cell within the two-photon
volume. (b) At 6 weeks of age, the number of glucose-induced exocytic
events is comparable with that of age-matchedWT (+/+) islets. Scale bars























































































































































Fig. 2 Islet morphology changes in db/db islets. Stage 1 and stage 2 db/
db islets have (a–d) a larger size (scale bar 200 μm) and (e) increased islet
insulin content compared with WT (+/+) islets. (f) Insulin secretion,
expressed as percentage insulin content for WT (+/+) and stage 1 and
stage 2 db/db islets in response to 3 and 15 mmol/l glucose. (g)
Immunostaining shows a selective expansion in beta cells compared with
alpha cells in stage 1 and 2 db/db islets compared with WT. Scale bar
50 μm. *p< 0.05; **p< 0.01; ***p< 0.001. Gluc, glucagon
Diabetologia (2016) 59:1222–1230 1225
test) but no significant difference in the peak glucose-induced
calcium response (Fig. 4a). In contrast, stage 2 islets showed
reduced calcium responses (Fig. 4a). This result indicates that
the increase in granule–granule fusion at stage 1 is not due to
an increased calcium response and instead suggests specific
upregulation of the granule fusion process. This conclusion is
supported by experiments using high extracellular potassium
as a stimulus that directly depolarises cells and bypasses
glucose metabolism. The high potassium-induced calcium
response was similar in stage 1 db/db as in WT islets
(Fig. 4b) but there was greater insulin secretion (Fig. 4c).
This evidence for an enhanced exocytic capacity in stage 1
db/db islets is supported by quantitative real-time PCR
(qPCR) data, which show upregulation of the mRNAs for
soluble N-ethylmaleimide-sensitive factor attachment
protein receptors (SNAREs), Snap25 and Vamp2, although
the Stx1amRNA level does not change significantly (Fig. 4d).
Our data also indicate the mechanism responsible for
decreased insulin secretion at stage 2. Stage 2 islets
showed continued upregulation of the mRNA for
SNAREs (as measured by qPCR; Fig. 4d), an enhanced
high extracellular potassium response and an intact
potassium-induced calcium response compared with WT
islets (Fig. 4b). However, their glucose-induced calcium
response was much lower (Fig. 4a). Although we haven’t
explored this in detail, the reduced mRNA for Slc2a2 (which
encodes glucose transporter 2 [GLUT2]; Fig. 4d) suggests that
beta cells at stage 2 are still secretory competent but are
defective in glucose sensing.
Granule fusion behaviour in stage 1 prediabetic islets Our
findings in stage 1 islets demonstrate increased insulin granule
fusion. However, we also noticed a difference in the spatial
pattern of granule fusion, with evidence for spatial clustering
of fusion sites that was not seen in WT (see Fig. 3a). To
quantify this we measured the spatial coordinates of all fusion
events. We then looked at a 4 μm2 area around each individual
fusion event and determined the frequency with which one or
more other fusion events had occurred. In WT (and stage 2)
islets, we observed that the frequency of other fusion events
occurring around each pre-existing fusion event became sig-
nificantly lower as the number of fusion events within this
area increased (Fig. 5a; 27 WT and 46 db/db islets; 845 WT
vs 1,514 db/db fusion granules). This suggests that, at least on
this small scale, there is little evidence for the clustering of
insulin granule fusion events inWT islets. In contrast, in stage
1 db/db islets, the frequency of multiple events (even up to ten
events) remained high (Fig. 5a; 4.62% of events had seven or
more fusion events within 4 μm2 in WT vs 22.71% in stage 1
db/db islets). A closer study (which was limited by our optical
spatial resolution) showed that repeated fusion had occurred
within the same region of interest (Fig. 5b). Inmany cases, this
led to a build-up of fused granules suggesting sequential,
compound exocytosis in which granules fuse with each
other (Fig. 5c). To quantify this behaviour, we chose an
arbitrary threshold of at least seven granules within a
4 μm2 area as suggestive of compound exocytosis and of
less than seven granules as suggestive of primary exocyto-
sis. Both the total number of primary exocytic events and
Table 1 Phenotype of 6-week-old WT and stage 1 db/db mice
Variable +/+ db/db p valuea
AUC (mmol l−1 min−1) 916 ± 43 1,076 ± 108 0.24
FBG (mmol/l) 6.3 ± 0.5 7.6 ± 1.0 0.34
Islet diameter (μm) 145 ± 7 132 ± 11 0.41
Islet insulin content (ng/islet) 40.2 ± 10.3 43.2 ± 8.7 0.83
Islet insulin secretionb
(% of insulin content)
1.23 ± 0.43 1.43 ± 0.41 0.75
Data are expressed as the mean± SEM. n = 3 for all values
a Student’s t test
b In response to 15 mmol/l glucose





































































































Fig. 4 Characterisation of beta cell changes in stage 1 and 2 db/db islets.
(a) Glucose-induced islet calcium responses are comparable between WT
(solid line) and db/db stage 1 islets (grey dotted line) but reduced in db/db
stage 2 islets (black dashed line). Scale bar 50 μm. (b) Potassium-induced
islet calcium responses are comparable among WT (solid line), db/db
stage 1 (grey dotted line) and db/db stage 2 (black dashed line) islets. (c)
Responses to 50 mmol/l KCl show enhanced insulin secretion at stage 1
and 2 in db/db compared with WT (+/+) beta cells. (d) qPCR shows
elevations in SNARE mRNA expression at stage 1 (light grey bars) and
2 (dark grey bars) but a reduction in Slc2a2 mRNA at stage 2 in db/db
comparedwithWT (white bars) beta cells. *p< 0.05, ***p< 0.001 vsWT
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the proportion of compound exocytic events increased
significantly in stage 1 db/db islets and decreased to below
WT in stage 2 db/db islets (Fig. 5d).
Our data is consistent with, but does not prove, compound
exocytosis. We therefore undertook serial block-face electron
microscopy of islets that had been fixed after 15 mmol/l
glucose stimulation for 7 min (Fig. 6a, b and ESM Video 1).
We could readily identify chains of fused insulin granules with
a single exit point (i.e. fusion pore) at the cell membrane, thus
providing good evidence for granule–granule fusion.
Interestingly, we also found evidence of granule–granule
fusion without contact with the cell membrane (Fig. 6c).
Chains of fused insulin granules were found in both WT and
db/db islets and could be part of the granule maturation
process. Our evidence for granule–granule fusion is depen-
dent on the appearance of continuity and the lack of a
membrane between granules. Further work will be required
to show granule–granule fusion and content mixing.
However, and consistent with previous findings [21], analysis
of the live-cell data (Fig. 5) showed that although most
granule fusion events are similar in size (see Fig. 5b), some
are larger and therefore could arise from multigranular
objects that fuse with the cell membrane (ESM Fig. 1
[21]). We conclude that live-cell imaging and electron
microscopy indicate that at stage 1 the prediabetic phenotype
shows an increased prevalence of compound exocytosis.
Discussion
We used GTTs to classify disease severity in db/db animals
and demonstrated that changes in beta cell function do occur
in prediabetes. In stage 1 db/dbmice, the GTT is the same but
FBG is elevated compared with WT mice; however, we
observe an increase in islet size and insulin content, which
supports previous work demonstrating beta cell expansion
in early disease. Our new finding is that function is also
altered, including an increase in basal insulin secretion and
an increase in the number of glucose-induced granule fusion
events, the latter due to upregulation of compound exocytosis.
Beta cell function in prediabetesOur evidence demonstrates
significant changes in the secretory function of islets in
prediabetes.
First, we observed an increase in basal (i.e. at 3 mmol/l
glucose) insulin secretion. This increase is maintained in stage
2 islets, consistent with previous work on the db/db model
[20, 22, 23]. The increased secretion could be driven by the
elevated basal intracellular calcium concentration that was
previously observed at stage 2 [20] and which we now show
also occurs in stage 1 islets (Fig. 4a), possibly through
calcium-dependent granule mobilisation step [24].
Second, after stimulation, we showed that stage 1 islets
have more glucose-induced insulin granule fusion events
compared with WT islets (Fig. 3a), but with no change in
the calcium response (Fig. 4a). Since the high potassium-
induced response is also bigger, again with no increase in
the calcium response, these data are consistent with upregula-
tion of the terminal stages of the stimulus secretion pathway
that are downstream of calcium entry. This conclusion is
supported by the increase in mRNA expression of some of
the SNAREs (Fig. 4d).
A direct comparison of insulin secretion from islets
(Figs 1c, 2f) shows that the fold increase in secretion is
decreased at all disease stages in db/db islets. This largely
reflects the reduced capacity of the beta cells to respond to
glucose at stages 2–4. However, at stage 1 this is mostly
due to increased basal secretion: glucose-stimulated secre-
tion increases when measured per islet (Fig. 1c) but remains
the same when measured per insulin content (Fig. 2f).
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Fig. 5 Compound exocytosis is increased in stage 1 db/db beta cells. (a)
Analysis of a 4 μm2 region around each exocytic event shows that the
frequency of observing more than seven events is much lower in WT
(dashed line, circles) and stage 2 db/db (dotted line, squares) islets but
not stage 1 db/db islets (solid line, triangles). (b) Evidence for multiple
granule fusion events occurring within the same region of interest. (c)
This is shown as an image series with the numbers (i), (ii), and (iii)
indicating the peaks of fluorescence as each granule fuses. Scale bar
1 μm. (d) Histograms of primary (under seven events within a 4 μm2
region) exocytosis and compound exocytosis show increases in stage 1
and decreases in stage 2 db/db compared with WT (+/+) beta cells.
**p< 0.01, ***p< 0.001. 2P, two-photon; AU, arbitrary units; ROI, re-
gion of interest
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Given the similarities in islet insulin secretion between
WT and stage 1 db/db islets, the large increase in insulin
granule fusion numbers was surprising: the explanation for
the discrepancy between increased fusion events but
comparable secretory output is not clear. One possibility is
heterogeneity in the beta cell content and function, which
has been observed in late-stage disease [20], possibly due to
cell dedifferentiation [25]. Heterogeneity might give rise to
some cells that contain insulin but are non-responsive, there-
fore explaining the increase in granule fusion events in the
other cells. An alternative possibility is that insulin granule
fusion at stage 1, in particular via compound exocytosis, is
less efficient. This idea is difficult to test, but we might expect
that multiple granules releasing content through a common,
single, fusion pore would at least have slower kinetics of
insulin release compared with normal fusion, in which each
granule releases its content through its own fusion pore.
Compound exocytosis is rarely observed in WT cells
after glucose stimulation but is specifically upregulated,
for example with glucagon-like peptide 1 (GLP-1) stimulation
[26]. Although it is possible that stage 1 db/db islets selec-
tively enhance pathways that normally regulate compound
exocytosis, we suggest that this is more likely to result
from non-specific upregulation of the exocytic machinery.
Given the critical importance of the balanced expression of
SNARES for regulating granule fusion [27], it is possible
that an imbalance might lead to an increased prevalence of
compound exocytosis.
Comparison with disease progression in humans Our
phenotypic data showing disease progression in db/db mice
are consistent with previous work [28] and with the
progression of type 2 diabetes in humans [3]. In
humans, compensatory increases in the insulin response
b
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Fig. 6 Electron microscopy
evidence for compound
exocytosis. (a, b) Serial block-
face electron micrographs
through two typical examples of
multigranular compound
exocytosis in db/db islets
stimulated with 15 mmol/l
glucose. Low magnification
images show the area that is
enlarged and shown as serial
sections (i–iv) 50 nm apart taken
through a compound exocytic
event composed of multiple fused
granules. The reconstructed
models show the spatial
relationships between each fused
granule (in colour) and also
identify the adjacent cell plasma
membrane (white mesh). (c) In
some cases, granules within the
cell were fused together but made
no contact with the cell surface, as
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Fig. 7 Spider graph showing changes in db/db islet and beta cell secre-
tion at different stages of disease. Each line is centred on the mean for
each variable and the width represents the SEM. Note, for clarity, the
AUC is inverted and shown as a fraction of 5,000 mmol l−1 ×min.
Green, WT; yellow, db/db stage 1; orange, db/db stage 2. 2P, two-photon
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occur in stage 1 disease [18, 29] and are associated with
increased islet size and insulin content [8, 9]. As the disease
progresses, insulin content decreases [30] and, as we observed
in the mouse, glucose-induced insulin secretion is reduced
[31, 32].
Humans with relatively poorer insulin sensitivity tend to
have a higher insulin secretion [33]. The product of insulin
sensitivity and pancreatic responsivity (the disposition index),
has a hyperbolic relationship [33] that does not normally
change over time. However, evidence, from obese humans
that are developing insulin resistance, shows that insulin
secretion can increase according to the demand [34].
Another human study showed increasing insulin secretion
up to a maximum at a FBG of 5.6 mmol/l, followed by a
decline [29]. Longitudinal studies show that individuals
who progressed to diabetes did not have compensatory
increases in insulin secretion; in contrast, those that did,
did not progress [18, 35]. Consistent with this, animal
models of diabetes also show increased insulin secretion
in early disease [11, 36, 37].
Our data represent a step towards understanding the
mechanisms that underlie increased insulin secretion in
prediabetes and show that, in addition to an expansion in cell
numbers, functional changes are occurring in the beta cell.
Summary of disease progression to diabetes The changes in
phenotype and function associated with WTand stage 1 and 2
db/db animals is shown in a spider plot (Fig. 7). At stage 2, the
dramatic drop in the number of granule fusion events (Fig. 3)
is coincident with the increase in AUC, thus closely aligning
beta cell dysfunction with a loss of glucose homeostasis.
These stage 2 beta cells still secrete insulin in response to high
extracellular potassium (Fig. 4b), which is consistent with
effectiveness of sulfonylureas (potassium channel blockers)
for treating diabetes [38]. The possibility of an upstream
defect is supported by the reduced calcium response to
glucose that we and others have observed [20, 23] and the
decrease in Slc2a2 mRNA levels (Fig. 4d [39]). In type 2
diabetic human islets, the loss of glucose-induced secretion,
but with little change in arginine-induced insulin secretion,
also suggests defects in glucose sensing [32]. In addition to
these upstream defects, the altered expression of exocytic
machinery that we observed is consistent with evidence
that genetic variation affecting downstream factors, such
as granule docking and decreased calcium sensitivity, are
involved in the development of type 2 diabetes [40]. Thus,
later disease is probably due to a combination of aberrant
exocytosis and changes in glucose sensing.
Conclusion We conclude that altered beta cell function is
intimately associated with prediabetes and progression to
diabetes.
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